Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + Pemetrexed in Advanced NSCLC, Urothelial Cancer, and Mesothelioma
NCT04173338Phase 1Terminated
- Sponsor
- Augusta University
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), urothelial carcinoma (UC) and malignant mesothelioma, sponsored by Augusta University. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Jan 2020; status: terminated.
02
Drugs
cabozantinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)urothelial carcinoma (UC)malignant mesothelioma
Beyond the preview
Go deeper on NCT04173338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173338.